Spravato® Therapy at Hudson Mind Ushers in New Era of Accessible Care for Treatment-Resistant Depression

News provided by

Apr 15, 2024, 23:53 ET

The groundbreaking nasal spray is eligible for insurance coverage.

NEW YORK, April 11, 2024 /PRNewswire/ -- Hudson Mind, an interventional mental health clinic in New York City, announces the addition of Spravato^® (https://mind.hudson.health/treatments/spravato/). The integration of Spravato opens the door to more accessible treatment options for patients with major depression.

Patient recovery room in Hudson Mind's West Village practice. (PRNewsfoto/Hudson Mind)

Spravato is a nasal spray made from a derivative of ketamine called esketamine, which activates biological processes that boost the neurotransmitter Glutamate in regions of the brain associated with mood. Since its FDA approval in 2019, studies have demonstrated Spravato's fast-acting relief and enduring efficacy—especially for patients with treatment-resistant conditions.

The World Psychiatry Journal estimates that at least 30% of people who have been diagnosed with depression qualify as treatment-resistant, indicating that they have not responded to two or more antidepressant trials. Spravato is a natural addition to Hudson Mind's commitment to bridging the gap between conventional and cutting-edge care.

Hudson Mind psychiatrist Dr. Marcel Green is eager to introduce more patients to the burgeoning interventional mental health landscape, starting with Spravato.

"For too long, patients have felt frustrated by treatment options limited in precision that have not significantly advanced in decades. With widespread insurance eligibility, Spravato brings more precise interventions to the forefront of mainstream, accessible care," says Dr. Green. "At Hudson Mind, we emphasize that ketamine represents a revolutionary advancement in mental health care. Spravato coupled with integration therapy—which helps translate the experience into real, pragmatic changes— yields a powerful impact that is noticeable early in treatment. Its promotion of neuroplasticity within the brain both accelerates and solidifies the development of new thinking patterns, broadens emotional range, and forges mental and emotional resiliency."

Spravato joins a range of clinically-proven interventions at Hudson Mind, including IV ketamine therapy for depression and anxiety, Transcranial Magnetic Stimulation for depression and obsessive compulsive disorder, and Stellate Ganglion Blocks for chronic anxiety and Post-Traumatic Stress Disorder.

About Hudson Mind
Hudson Mind is the interventional mental health branch of Hudson Health's multidisciplinary practice, which includes pain management and regenerative & longevity medicine. Hudson Mind combines conventional psychotherapy and pharmacology with cutting-edge interventions proven to break depressive patterns, reset the nervous system, and activate new neural connections in the brain. The practice is located in New York City's West Village. To learn more, please visit mind.hudson.health.

SOURCE Hudson Mind